Merck & Co., Inc. (NYSE: MRK) is one of the most undervalued blue chip stocks to buy according to hedge funds. On July 21, ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Employees of the technology transfer center ANAXAM and researchers from the Paul Scherrer Institute PSI used the unique ...

Vinay Prasad, a top FDA official, suddenly departed after a series of controversial decisions about a Duchenne gene therapy ...

Can a drug that lowers “bad” cholesterol — and also raises the so-called “good cholesterol,” HDL — help to prevent ...

Along with its second-quarter results on July 29, Merck MRK announced a new multi-year optimization initiative, which is ...

The scale of the Merck layoffs has not been revealed, but the company indicated that it would target roles in the ...

Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Merck’s CEO recently shared insights on minimal impacts from EU tariffs and highlighted challenges in Gardasil production.

Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Trump’s trade deal with the E.U. may lead to higher prices for brand-name drugs in the U.S., including Ozempic and Wegovy, ...

On Tuesday, Merck ( MRK -1.56%) wasn't one of the better-performing pharmaceutical stocks. In contrast to certain peers, the company's share price declined following the release of second-quarter ...